IDH1 and neoplasm: To test the hypothesis that metabolic flexibility might be particularly constrained in tumor subtypes bearing IDH1 mutations and overproducing 2HG, we took advantage of an MCF10A cell line with an endogenous heterozygous knock-in of the clinically relevant R132H mutation generated via recombinant adeno-associated virus technology [51].